Duvyzat® treatment initiation1
Adverse event reporting information can be found at the bottom of this page.
Click HERE for prescribing information.
Baseline assessments before treatment
Baseline assessments for all patients
- Platelets and Triglycerides: Obtain and evaluate baseline platelet counts and triglycerides prior to initiation of Duvyzat®. Do not initiate Duvyzat® in patients with a platelet count less than 150 x 109/L
Additional baseline assessments for certain patient profiles only
- ECG: In patients with underlying cardiac disease or in patients taking concomitant medications that cause QT prolongation, obtain ECGs prior to initiating treatment with Duvyzat®, during concomitant use, and as clinically indicated
Initial dosing
- The recommended dosage of Duvyzat® is based on body weight
- Administered orally twice daily with food using the graduated syringe
- If a dose is missed, patients should not take double or extra doses
Recommended Duvyzat® starting dosage
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.
Adverse events should also be reported to ITF Pharma Ltd Medical Information on: 0800 098 4040 or UK.Medical.Information@italfarmacogroup.com
Product Quality Complaints should also be reported to ITF Pharma Ltd Medical Information on: 0800 098 4040 or UK.Medical.Information@italfarmacogroup.com
References
- Duvyzat Summary of Product Characteristics, MHRA, https://www.medicines.org.uk/emc/product/100605/smpc
